How ImmunityBio’s ANKTIVA combo is challenging glioblastoma’s immune collapse model
New Phase 2 data suggest ImmunityBio’s ANKTIVA plus CAR-NK combo could restore immune competence in glioblastoma. Find out why it matters.
Is deceased donor marrow a viable backup graft? First human data from Ossium says yes
Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.
BioTissue divests surgical and wound care business to BioStem, sharpening focus on ocular regeneration
BioTissue Holdings, Inc. has completed the divestiture of its non-ocular surgical and wound care business to BioStem Technologies, Inc. in a transaction valued at approximately $15 million upfront, with potential earnouts tied to regulatory and commercial milestones. The deal transfers ownership of the Neox and Clarix product lines, along with a seasoned commercial team and […]
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal […]
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to […]
Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?
GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from […]
Naturmega’s Ruby-O shows bioavailability edge over standard fish oil in peer-reviewed trial
Naturmega’s Ruby-O Balance showed better triglyceride response at a lower dose than fish oil. Find out what this means for the future of omega-3 delivery.
Can ketamine treatment clinics like Serenity redefine psychiatric care delivery in suburban America?
Serenity expands ketamine therapy in Florida. Find out how this signals a shift in psychiatric care access and what clinicians are watching next.
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.